Evidence map›Paper›PMID 34774760›Full record

ArticleBiochimica et biophysica acta. Proteins and proteomics2022

Immune response pattern across the asymptomatic, symptomatic and convalescent periods of COVID-19.

Yang Chen, Nan Zhang, Jie Zhang, Jiangtao Guo, Shaobo Dong, Heqiang Sun, Shuaixin Gao, Tingting Zhou, Min Li, Xueyuan Liu and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochimica et biophysica acta. Proteins and proteomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yang ChenCenter for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China; School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Nan ZhangCenter for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China; School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China.
Jie ZhangNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Jiangtao GuoCenter for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.
Shaobo DongMacheng Center for Disease Control and Prevention, Huanggang 438300, China.
Heqiang SunDepartment of Laboratory Medicine, the Second Medical Center, Chinese PLA General Hospital, Beijing 100853, China.
Shuaixin GaoCenter for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.
Tingting ZhouCenter for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China.
Min LiNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Xueyuan LiuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China; Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.
Yaxin GuoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Beiwei YeNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Yingze ZhaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China.
Tongqi YuMacheng Center for Disease Control and Prevention, Huanggang 438300, China.
Jianbo ZhanHubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China.
Yongzhong JiangHubei Provincial Center for Disease Control and Prevention, Wuhan 430079, China.
Catherine C L WongCenter for Precision Medicine Multi-Omics Research, Peking University Health Science Center, Peking University, Beijing 100191, China; School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China; Peking University First Hospital, Beijing 100034, China; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China; Advanced Innovation Center for Human Brain Protection, Capital Medical University, Beijing 100069, China. Electronic address: catherine_wong@bjmu.edu.cn.
George F GaoNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China; CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.. Electronic address: gaof@im.ac.cn.
William J LiuNHC Key Laboratory of Biosafety, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention (China CDC), Beijing 102206, China; Department of Epidemiology, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China.; Research Unit of Adaptive Evolution and Control of Emerging Viruses, Chinese Academy of Medical Sciences, Beijing 102206, China. Electronic address: liujun@ivdc.chinacdc.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present an integrated analysis of urine and serum proteomics and clinical measurements in asymptomatic, mild/moderate, severe and convalescent cases of COVID-19. We identify the pattern of immune response during COVID-19 infection. The immune response is activated in asymptomatic infection, but is dysregulated in mild and severe COVID-19 patients. Our data suggest that the turning point depends on the function of myeloid cells and neutrophils. In addition, immune defects persist into the recovery stage, until 12 months after diagnosis. Moreover, disorders of cholesterol metabolism span the entire progression of the disease, starting from asymptomatic infection and lasting to recovery. Our data suggest that prolonged dysregulation of the immune response and cholesterol metabolism might be the pivotal causative agent of other potential sequelae. Our study provides a comprehensive understanding of COVID-19 immunopathogenesis, which is instructive for the development of early intervention strategies to ameliorate complex disease sequelae.

Indexed as

Asymptomatic InfectionsConvalescenceProteomicsCase-Control StudiesCholesterolCOVID-19Enzyme-Linked Immunosorbent AssayHumansImmunityMyeloid CellsNeutrophilsSARS-CoV-2CholesterolCOVID-19Immune responseMass spectrometryProteomics

Identifiers

PMID34774760
PMCPMC8580567

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.